Reddit Posts
Scynexis Inc earnings beat by $1.01, revenue topped estimates
Deadly fungal infection sweeps across U.S. (NASDAQ:SCYX)
What is a better play SCYX or ML?
Michael Burry’s Latest Holdings (Scion Asset Management)
Michael Burry reveals investment in Scynexis catching shorts pants down.
Michael Burry buys SCYX - as a pharmacist, I have been holding SCYX for years now
SCYX looks like a perfect WSB candidate 😍. 50% publicly owned
SCYX- Top 50 most shorted stock on NASDAQ. 23% short ownership. 23 million share float. $4+ in cash. Stock trades around $6 per share. 60% held by Institutions (of the 69 Institutional positions, 65 are long only). FDA just approved it's drug, Brexafemme. On Pharmacy shelves now.
$SESN Pt. 2 – When I Gaze into the Future and Make things up
Swipe! I'm bullish af on SCYX! They are launching the only medication that is effective against drug resistant strains of candida. 10 years exclusivity! Super bargain price. This is a steal! I've been waiting for this since about 2014! LFG!!
Something seems fishy with SCYX dropping by over 11% after receiving market approval
Crowdfunding campaign for whistleblowers on illegal trading practices
Thoughts on SCYX? FDA approval pending, target price significantly higher than current price?
Thoughts on SCYX? FDA approval pending, target price significantly higher than current price?
Lets keep things fresh... Vaginal Yeast Infection SCYX had glorious treatment news, nice Calls & OI
SCYX is about to cure a whole lot of Vaginas! (new website)
SCYX is about to cure a whole lot of Vaginas!
Mentions
SCYX had some news this morning but not doing much https://finance.yahoo.com/news/scynexis-receives-fda-qualified-infectious-130000043.html
My top 5 penny biotechs in order of preference, baby: 1. SPRO, 2. SLS, 3. MIST, 4. DRTS, 5. SCYX. First 3 have events coming up in next 1 or 2 months that could move the stock either up or down. Last 2 are longer-term plays.
Biotechs I like SLS, SPRO, SCYX, baby
I’ve got my eye on SCYX … check it out. Super beat down antifungal company with an FDA approved product, ibrexafungerp They have the patent on an entirely new class of antifungals. Super low float too
Oh yeah baby! I mentioned SCYX pump today here about an hour ago. I started buying that about a month ago and am averaged in to 7,000 shares at 71 cents.
I know I’ve commented about SCYX a few times over the past few days, but it’s the only thing in my port moving up today. It seems like its validation reset has started, and I don’t think it’s done
SCYX starting to wake up? Volume up the past couple days and now +7-8% in the premarket. There’s a good argument for a valuation reset here
SCYX nice jump on open with (relatively speaking) some half decent volume. I’m not sure when it’ll hit, but this does feel like it has a good run coming in the next week or two
SCYX is interesting and is not one that’s already made a run. There’s no near-term catalyst but also no near-term existential risk, and from what I can tell they’re trading for less than they’re worth in cash today. They already had 12-18 months of burn and that’s now >2 years with their GSK settlement, not including revenue they generate next year when GSK restarts Brexafemme sales. ~$25M market cap vs what I believe is ~$70M in cash and short-term assets and ~$14M in liabilities on a biotech that has funding through the next phase of their pipeline and has already successfully commercialized a therapy in their current asset class. Short interest isn’t that high but volume is so low that it’s like 3 days to cover. Maybe I’m missing something but this seems way under-valued and primed to leg up
SCYX upcoming events: filing by partner Glaxo of NDA for their first generation antifungal (timing not clear; maybe Q1 2026?); start of Phase 1 for IV route for their second generation antifungal; start of Phase 2 for same second gen antifungal via oral route. Both these to start Q1 2026. Per Q3 earning press release on Nov. 5 they state they have "more than 2 years" of cash runway.
$CYN upcoming earnings $CYCU $SCYX
$CYCU is definitely the one that needs attention. This literally has a government contract JUST TODAY. I believe this will go past 4$ tomorrow and maybe moon depending on retail sentiment. $CYN Is earning around Nov 12,2025, that's a good date to remember. $SCYX is currently waiting to receive funds in significant portions over the course of the month which may giga pump it over time.
$CYCU pumping right now it’s not too late to jump in. I am also in $CYN it’s set up for a short squeeze Also buying $SCYX later this week with my $CYCU profits. Keep an eye out for $VMAR as well it could pump. Hearing good things about $ALTS but this is going to be a few months play I’ll buy in once I get some profits this week. $BYND earnings report seems to be a bear trap and might pump after the call tomorrow but idk about that one
New play is $SCYX Positive analyst rating and a PT of $3. Volume is picking up a lot so could already run in AH!
$SCYX, I just bought 17,942 shares.
Again you've mixed up SCYX with SYDX. I am long SCYX but it's time you fix this error since it confuses people
$SCYX up 11% after hours. Insider buying, catalyst tomorrow?
Guys check out SCYX Have a fda announcement tomorrow as well This thing could rocket 🚀
Just a heads up. As I was looking into this I discovered that there are two companies with very similar names. There's Sydnexis, a privately held company which researches myopia and is the company described in the post with the 85% chance of approval for SYD-101. And then there's Scynexis, an antifungal biotech that is under the ticker SCYX. [https://sydnexis.com/](https://sydnexis.com/) [https://www.scynexis.com/](https://www.scynexis.com/)
Added some SCYX, thank you for posting!
The whole text: PoA Summary : SYD-101, a low-dose atropine eye drop developed by Sydnexis (ticker SCYX), is under FDA review for pediatric myopia with a PDUFA date of October 23, 2025. The New Drug Application (NDA) is backed by the STAR Study, the largest Phase 3 trial for this indication, involving over 850 pediatric patients aged 3 to 14 years. The randomized, double-masked, placebo-controlled trial demonstrated significant efficacy in slowing myopia progression and confirmed a favorable safety profile over a three-year treatment period. Although traditional efficacy metrics like objective response rates are not applicable, the trial's outcomes and regulatory feedback suggest a clinically significant benefit, supported by a positive CHMP opinion from the EMA for European marketing authorization. SYD-101's stabilized low-dose atropine formulation addresses issues of instability and variable concentration seen in compounded versions, enhancing consistency and regulatory confidence. As a first-in-class therapy for pediatric myopia progression, SYD-101 faces no direct competition in the U.S., which may facilitate an expedited regulatory process. With no Complete Response Letter issued and a positive history of regulatory engagement, including FDA acceptance of the NDA and EMA's favorable opinion, the approval outlook remains strong. Considering the robust Phase 3 data, the significant unmet medical need, the established safety profile, and regulatory advancements, the Probability of Approval for SYD-101 is estimated at 85%. This estimate is consistent with historical NDA success rates for small molecules demonstrating positive Phase 3 results in novel indications while factoring in typical review uncertainties. Treatment : Pediatric myopia (progression) Description : The FDA has accepted the NDA for SYD-101, a once-daily low-dose atropine eye drop to slow the progression of pediatric myopia. Based on data from the pivotal Phase 3 STAR Study, the PDUFA target action date is October 23, 2025. If approved, SYD-101 would become the first pharmaceutical treatment for this condition in the U.S.
AVLNF is a sub $100M Canadian mining company with huge lithium and high risk REE reserves that's not getting a lot of hype yet. I will continue monitoring it. SCYX is my deep value play in the biotech space. They have more cash on hand than their market cap, and has actual FDA approved drugs in a high need area. Just going through temporary commercialization difficulties with GSK. As always - NFA.
Any thoughts on SCYX? Is RVPH the popular bet for Oct?
I was in on SCYX since 2020. Kept doubling down, selling some when it popped, and chasing the bottom. It’s had a 1 year price target that started at $22 (before it was a penny stock) and last I looked, 1 year target was $8. That company constantly seems to find a way to self destruct. I sold over 5k shares in July and August. Looks like I missed a big move
I like this play. Also like SCYX penny stock pharma
Scynexis is one that has crazy small float and heavily shorted too. I’m about to buy some SCYX shares and $2.50 calls. See if he picks another company that has cash runway and a drug on the market like SCYX
any other bio-tech’s you like rn? Im also kinda apalled at Biogen’s fall from grace, i get it, Aducanumab didnt work out but they got a p solid pipeline. but the only other cheap biotech’s im in are SCYX and Inovio
Only two out of the four companies you mentioned actually have FDA-approved drugs: Geron (GERN) and SCYNEXIS (SCYX). Geron's Rytelo (imetelstat) is approved for low to intermediate risk MDS, a condition that affects a relatively small patient population (around 60,000 - 100,000 people in the U.S.). While there is some demand, it’s not exactly a blockbuster drug, and there are several other alternatives. SCYNEXIS’s Brexafemme (ibrexafungerp) was approved for treating vaginal yeast infections, but sales were halted due to manufacturing issues after the company found potential cross-contamination risks. GSK, which now handles its commercialization, is working on a solution, but the drug is currently off the market. So, if your argument is based solely on FDA approvals, it’s not as strong as you think. Having an FDA-approved drug doesn’t automatically make a stock a better investment - especially when one isn’t a major market mover and the other isn’t even being sold right now.
Look into ITRM, GERN, ATOS, SCYX. Much closer to making you money on being a bag holder.
SCYX looks good. Their lead product is BREXAFEMME. They have an additional pipe line product going into phase 1 or 2. Good pick.
I like SCYX and I look for beat down companies with drugs in phase 3 trials or in this case a company with a patent on the entire drug class and a few approvals to generate sales / performance bonuses from partners to not go to $0
Penny stock SCYX. It’s valued less than its cash and has the patent on an entire class of antifungal drugs … with one on the market and more approvals coming for more severe infection types
🫡👏 I haven’t traded in a while but I’m feeling GME 1/2026 $15 calls right now. It’s basically been banned here and I think we see volatility again soon. If you like penny stocks, check SCYX and NNOX. I’ll probably dive into those as well this month
Nice. I’m about to load up on SCYX for similar reasons. I feel it’ll get bought out and is way undervalued. Market cap is $57million
Once this rollover to my self managed IRA hits I’m going balls deep in HALO, GMAB, SCYX, GILD … and GME 1/2026 ITM calls. All I need is one more dumb pump over 15 months and I’m rich
I’m a pharmacist, PFE is a terrible bet. Cut that shit If you wanna buy calls go with Gilead or Takeda and long dated If you want something trading low, BIIB is 52 week low and also SCYX is a penny stock I like a lot (have been buying since $10 lol). If you want blue chip go with GILD or TAK. If you had the capital and balls of steel I would say buy puts on Lilly for December at $800 strike
I’ll get mine on SCYX one day. It trades soooo low and $2.50 calls are like $0.05. I try and buy a few + shares every couple months
I’m a big fan of SCYX and their patent on new class of Antifungal. I’m dumbfounded how undervalued that continue to be
I am buying SCYX. Penny stock be flying.
I have over 18k shares of SCYX. it's down right now and I'll end up buying more this Monday if it hits 1.7x or 1.6x. It's going to pop Q4 2024 imo of it doesn't get bought out before then This isn't financial advice, it's just what I'm doing.
SCYX in Q4 of 2024 you can thank.
Check out SCYX, promising anti fungal drug and likely a buyout candidate And as always GME is a ticking time bomb that will be volatile and an options traders wet dream
As a doctor I just want to say how many times I've lost money on drug start ups. The whole reason for stage III trials is we usually have no idea how it'll work out. Second a metabolic of a well tolerated generic drug (that is not standard of care for all breast CA but just hormone sensitive) isn't going to bring in all that much money. I put less than 5% of my portfolio in a start up Scynexis SCYX with an approved nivel antifungal ibrexafungerp already in use for vaginal and vulvovaginal candida infections. So already relatively safe as FDA approved (can cause birth defects though!). This weekend is a European Infectious Disease conference where results or updates from multiple trials for more serious (as in invasive life-threatening) illnesses are being presented. And while it is already up a little ( and up a lot two weeks ago after signing a deal with GSK) I am still kinda wishing I hadn't. So many more fail than succeed. On ATOS I have no clue what else they have in the pipeline. But tamoxifen is already well tolerated. I doubt a metabolite will be more effective as it is present with a parent drug by definition. Tolerability is all you generally get by going with a metabolite. My Mom took it for 5 years without any symptoms AT ALL and she's allergic to everything and sorta sensitive. It isn't that it won't work but pricing issues. What does it do that a cheaper generic won't? We doctors are getting fed up (as are patients) of drugs that are not novel or repackaged firms if cheaper drugs being sold for 10-1000x more. Not sure why I'm telling you all this other than having lost so much on what seemed promising drugs and as a doctor I'd read the Phase I and II trials then phase III either fail or fail to impress. I put to you that even if FDA approved it'll have to prove itself better head to head in survival rates against tamoxifen to warrant adoption and any piece of that small dollar market. Just be careful...slow and steady and retire in 50s...lol. I have.
SCYX price target $8 minimum
SCYX. Definitely an investment. Not necessarily a trade. Penny Biotech with approved antifungal and 11 years exclusivity. Nice entry point right now.
Thoughts on $SCYX? (Scynexis, manufactures a new drug called Brexafemme)
SCYX is my only stock that I know will be a homerun someday. First new antifungal in decades. Ibrexafungerp has already been approved as Brexafemme for severe or azole resistant vaginal yeast infection and is on most national formularies. Also testing very well against other severe fungal infections in a hospital setting. 12 years exclusivity in America and Europe. Id expect a buyout. Analyst avg. PT $20. Currently under $2 right now.
I started investing March 2021. Like a rookie i focused completely on stocks under $20. Mostly small caps. Alot of biotech. No stop losses. My portfolio is down BIG. Ive had some winners. The losers i hold onto because i just cant force myself to sell at a loss. So I average down. And wait. And commiserate with my fellow bagholders. AVTX, CASI, SCYX, ATER, BBIG, SOS, CEI, HUYA, AZRE, ZKIN. Down Down DOWN!!! So I hold. And wait. And complain. That is all.
SCYX. A BIOTECH UNDER $5 WITH REVENUE!! First non- azole fungicide in 20 years. Azoles weaken fungus so your body can fight the infection. Ibrexafungerp kills fungus. Approved and released as Brexafemme for vaginal yeast infections. Going through trials for various fungal infections. 12 years exclusivity in US and EU. Today its at $3.60. Avg. PT is $21. With fungal infections on the rise, Ibrexafungerp will be huge.
Unfortunately this list is FAR from complete. Every small cap I have is way down. AVTX, AZRE, CASI, SCYX, ZKIN
Michael Burry just dumped everything except CVS LMT DNOW SCYX
Only if he wants to include a 10-page explanation of why he thinks SCYX is worth a fuck.
Buy calls on DWAC that expire later than Feb 21. Buy calls on KRYS that expire later than the end of March. When KRYS doubles again, sell. Put half of that money into KRYS common shares. When the DWAC app goes live at the end of Feb, sell the calls and put half into DWAC common. Take half of the remaining cash and put it into SCYX common before March 22 when they announce earnings. Take the remaining cash and Venmo it to me with an order of chicken tenders and honey mustard. Note that if the upcoming KRYS study results come out later than March 22 then you won't be able to buy SCYX before their earnings, but whatever since this certainly isn't financial advice and oh by the way, I am invested heavily in all of these companies mentioned.
Background: Young investor, 30+ year investment horizon. Looking to be aggressive while I still have many years of earning potential ahead. Currently have time to research and pick stocks. Plan to start DCAing into index funds in a couple years CLF (32%) - Been swing trading and selling covered calls on this one since it was at $16 back in April. Believe company will announce great results + guidance at earnings next month. PENN (18%) - Casino business with a history of profitability that’s been on my watchlist since they acquired Barstool Sports. Most interesting way to play sports betting legalization in the US imo. Finally took the plunge after their earnings report dump a couple months back, been averaging down since $55. SOFI (15%) - Great leadership here, absolutely love the business. Still fairly high valuation, but I think there’s a short-term catalyst based on their bank charter application being approved. Add in their Galileo business, and this is a stock I’d like to hold forever. SRNE (8%) - Biotech company developing cancer treatments, non-opioid pain medicine, and various COVID related products. High-risk, high-reward. TLRY (6%) - Cannabis bag holder here. I’ve been selling calls on this one since august so I’m about at break even. In my head I know I should probably cut bait, but a rally in cannabis could take this back over $10 in a hurry. PSTH (6%) - Went relatively big into this SPAC after Ackman announced the UMG deal in August. Sold off most of my shares to lock in the 2021 tax loss. Trading below NAV there’s basically no downside risk, so I’m holding onto some shares on the off-chance the SPARC proposal is approved by the SEC. Learned my lesson on SPACs here. AQST (2%) - Biotech working on an orally-delivered treatment for seizures. Stock tanked 30% when the FDA delayed approval on their product labeling before the holidays. Small gamble that the sell-off was baseless and the drug is approved soon. SCYX (2%) - Another biotech which I believe to be undervalued. Developing anti-fungal treatments with one currently being sold in the US. $188M market cap, but potential peak sales target of $400M+. Also worth noting that Michael Burry added $1M worth of shares in his latest 13F Cash (11%) - I’m stockpiling cash in expectation of a market correction, looking to trim some positions on the next move up and get to roughly 20% cash. Magic internet coins (>1%)
Background: Young investor, 30+ year investment horizon. Looking to be aggressive while I still have many years of earning potential ahead. Currently have time to research and pick stocks. Plan to start DCAing into index funds in a couple years CLF (32%) - Been swing trading and selling covered calls on this one since it was at $16 back in April. Believe company will announce great results + guidance at earnings next month. PENN (18%) - Casino business with a history of profitability that’s been on my watchlist since they acquired Barstool Sports. Most interesting way to play sports betting legalization in the US imo. Finally took the plunge after their earnings report dump a couple months back, been averaging down since $55. SOFI (15%) - Great leadership here, absolutely love the business. Still fairly high valuation, but I think there’s a short-term catalyst based on their bank charter application being approved. Add in their Galileo business, and this is a stock I’d like to hold forever. SRNE (8%) - Biotech company developing cancer treatments, non-opioid pain medicine, and various COVID related products. High-risk, high-reward. TLRY (6%) - Cannabis bag holder here. I’ve been selling calls on this one since august so I’m about at break even. In my head I know I should probably cut bait, but a rally in cannabis could take this back over $10 in a hurry. PSTH (6%) - Went relatively big into this SPAC after Ackman announced the UMG deal in August. Sold off most of my shares to lock in the 2021 tax loss. Trading below NAV there’s basically no downside risk, so I’m holding onto some shares on the off-chance the SPARC proposal is approved by the SEC. Learned my lesson on SPACs here. AQST (2%) - Biotech working on an orally-delivered treatment for seizures. Stock tanked 30% when the FDA delayed approval on their product labeling before the holidays. Small gamble that the sell-off was baseless and the drug is approved soon. SCYX (2%) - Another biotech which I believe to be undervalued. Developing anti-fungal treatments with one currently being sold in the US. $188M market cap, but potential peak sales target of $400M+. Also worth noting that Michael Burry added $1M worth of shares in his latest 13F Cash (11%) - I’m stockpiling cash in expectation of a market correction, looking to trim some positions on the next move up and get to roughly 20% cash. Magic internet coins (>1%)
Opened a small position in SCYX so now I’m sure it’ll tank so hard, it’ll be delisted.
my TSLA 880 1/21 put up 82% today--- saved my ass considering literally all my YOLO stocks crapped the bed--- HCP, CRSP, TCHEY, SCYX, and SoFI--- rip my portfolio
TLDR…. Buy EXAS, CVS, LMT, GEO, CXW, DNOW, SCYX, and T…. Not financial advice.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: SCYX. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
And he picked up SCYX one of my favorite pharma plays.
What’s your thesis on SCYX becoming a meme stonk
> SCYX Biotech, drug discovery, antibiotics or some shit
Long $SCYX I am 100% YOLO on the stock and call options 135m market cap 20% float is short $7 stock, $21 TheStreet price target Michael Burry bought $1m shares... disclosed today LET'S GO
Were you the guy that was a pharmacist that put out a DD on SCYX a whole ago?
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: SCYX. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC.
I am a bot. You submitted a picture of a banned ticker, SCYX. This check will fire if you included unnecessary pictures that have bad phrases or a bad crop with news about cryptocoins, for example. Repost with the useless pictures omitted if you did that. Yell at /u/zjz if it's above 1.5 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.
SCYX - near all time low. Just had their anti-fungal Ibrexafungerp (first new class of anti-fungal in decades) Market cap is essentially equal to their cash flow from last quarter’s earnings. I’m holding some shares and 3/2022 $2.50-5 calls
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: SCYX. Message /u/zjz if they're above 1.5 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.
Cel Sci (CVM), Scynexis (SCYX)
I've been bitten so many times by biotech stocks that it's not even funny. SCYX was the most recent, but PROG was shaping up to do the exact same thing. Biotech is great if you are in on something that's going to be disruptive. From what my diabetic friends are telling me, nobody wants to have the sensor implanted. IMO it's a great technology but I just don't think it's disruptive.
You could be right. That has happened before. For example SCYX fell 18% the day their approval was announced in June. But it had shot up 53% in the days leading up to it. I am planning on going into greater detail on this in my next DD, but most stocks jump on approval. When they don’t, it’s usually because they had already been on a run. IMO $SESN still hasn’t had its FOMO run leading up to the big day. With a market cap of 650M and projected annual sales being 1-3 Billion, I think there is still plenty of room to run.
SCYX is the next big move! They've created the first cure for drug resistant candida which has a 30% mortality rate of those with bloodstream infection. They have 10 years exclusive rights. Projecting 600M in sales. Don't miss this!
SCYX is the next big move!
SCYX is the next big move!
SCYX is the next big move!
SCYX is the next big move!
SCYX is the next big move!
SCYX! Exclusive medicine is hitting shelves in August! 10 years exclusivity!
I am a bot. You submitted a picture of a banned ticker, SCYX. This check will fire if you included unnecessary pictures that have bad phrases or a bad crop with news about cryptocoins, for example. Repost with the useless pictures omitted if you did that. Yell at /u/zjz if it's above 1.25 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.
Somebody give this man an award. All my money is tied up on CVM, VXRT, SCYX, GME, AGEN, and CLVS leaps.
This is how SCYX is making me feel right now. They announced FDA approval and their stock plummeted $1.52 that day. Today they announced that the FDA granted them 10 years of exclusivity for their new drug and it closed down $.05.
SCYX 🍑 for us lady 🦍’s SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/scynexis-confirms-brexafemme-ibrexafungerp-tablets-123000897.html
Thoughts on SCYX? Dropped almost 12% today after receiving FDA approval for a new drug? Seems fishy. Short attack for a planned hostile takeover?
I think we should look into SCYX. Got market approval for a drug today and price dropped 11%+ so far. The stuck was undervalued even before this drop. This feels like a short squeeze opportunity.
I am a bot from /r/wallstreetbets. You submitted one or more banned tickers: SCYX. Message /u/zjz if they're above 1.25 billion-ish market cap and not related to crypto/pennies/OTC/SPACs.